Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

The medical device company has seen its growth rate take a hit in recent quarters. DexCom blames its restructuring, but rising demand for GLP-1 drugs could be an issue. The stock's valuation has ...

Across the recent three months, 5 analysts have shared their insights on DexCom DXCM, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Key Insights The projected fair value for DexCom is US$123 based on 2 Stage Free Cash Flow to Equity Current share... DexCom (DXCM) doesn't possess the right combination of the two key ingredients ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...

Keep a close eye on the game and mark off each space when the time comes. Different variations of our bingo cards can be generated and printed using the options below.